Bullish & Foolish
Full HYPR fundamentals All 466 on the Survival Watch

HYPRHyperfine, Inc.

Is Hyperfine struggling financially?

Yes, by its own account. Hyperfine told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$95.7M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 15months

    If the burn speeds up

    Empty by Sep 2027

  • 21months

    If it eases off

    Empty by Mar 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$43.5M

÷

Cash burned over the last 12 months

$29.1M

What Hyperfine told the SEC

…If the Company is not able to obtain additional financing and/or substantially increase revenue from sales, in the longer term, it could result in a substantial doubt about the Company's ability to continue as a going concern. Management believes the net proceeds from the recent offering, described under Note 9 – “Debt” and Note 10 – “Stockholders’ Equity”, and the Company’s anticipated revenue, provide an…

Hyperfine, Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 28.4% share-count increase The company issued stock. Each share now owns 22.1% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 57% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt